Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00882999 · ClinicalTrials.gov registry record · Phase 2
A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 245
- Enrollment target
NCT00882999 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 245 participants.
The verdict
NCT00882999, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 245 participants
- Enrollment target
Study Summary
To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.
Interventions
- DRUG Placebo
- DRUG LY2127399
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2009-04 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00882999
The ClinicalTrials.gov registry entry for NCT00882999 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00882999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00882999 about?
NCT00882999 is a clinical study titled "A Study of Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)". To look at the ability of LY2127399 to reduce magnetic resonance imaging (MRI) lesions at 12, 16, 20, and 24 weeks compared to placebo.
What is the current status of trial NCT00882999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 245 participants. The study started on 2009-04. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00882999?
The interventions under investigation include: Placebo (DRUG), LY2127399 (DRUG).
Who is sponsoring clinical trial NCT00882999?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.